Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan 30;189(4):E153-E159.
doi: 10.1503/cmaj.160142. Epub 2016 Oct 17.

Thrombotic microangiopathies: a general approach to diagnosis and management

Donald M Arnold  1 , Christopher J Patriquin  2 , Ishac Nazy  2
Affiliations
Review

Thrombotic microangiopathies: a general approach to diagnosis and management

Donald M Arnold et al. CMAJ. .
No abstract available

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Peripheral blood film showing classic findings of thrombotic microangiopathy. The image shows features of thrombocytopenia and microangiopathic hemolysis (Wright–Giemsa stain, original magnification × 50). Arrows show red blood cell fragments (i.e., schistocytes), which are substantially reduced. Image courtesy of Dr. Catherine Ross (Juravinski Hospital & Cancer Centre, McMaster University, Hamilton, Ont.).
Figure 2:
Figure 2:
Proposed diagnostic and treatment algorithm for thrombotic microangiopathy.,,, CT = computed tomography, ECG = electrocardiography, HUS = hemolytic uremic syndrome, LDH = lactate dehydrogenase, TTP = thrombotic thrombocytopenic purpura. *Refractory TTP: Persistent thrombocytopenia and persistent elevation of LDH level despite therapy. †Exacerbation: Recurrent disease within 30 days of stopping plasma exchange. ‡Remission: Response for more than 30 days after last plasma exchange. §Relapse: Return of disease more than 30 days after stopping plasma exchange.
See this image and copyright information in PMC

References

    1. Tsai HM. Untying the knot of thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome. Am J Med 2013;126:200–9. - PubMed
    1. Deford CC, Reese JA, Schwartz LH, et al. Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood 2013;122:2023–9, quiz 142. - PMC - PubMed
    1. Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16:1035–50. - PubMed
    1. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991;325:393–7. - PubMed
    1. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013;368: 2169–81. - PubMed

MeSH terms